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Up to 85% of adult patients with AML 
achieve complete response (CR) using 
current standard regimens and depending 
on pre-treatment characteristics. However, 
only ∼25–45% have a long-term leuke-
mia-free survival depending their age and 
 leukemia features. A number of clinical fea-
tures such as age, performance status, organ 
dysfunction, and biological characteristics 
of the disease (most importantly cytogenet-
ics) influence the outcome with several large 
studies showing the importance of karyo-
typic features of the leukemic blasts. Other 
prognostic indicators such as mutations or 
abnormal expression of specific genes such 
as MLL, CEBPA, FLT3, NPM1, DNMT3A, 
TET2, ASLX1, IDH1, IDH2, WT1, MN1, 
BAALC, and ERG have been recently 
described and are particularly useful in 
assigning risk to patients with diploid AML 
(intermediate risk cytogenetics group). 
Clearly, these data support the notion that 
neoplastic change is the culmination of a 
number of molecular events that result in 
deregulated cellular pathways with more 
molecular aberrations leading to diseases 
that are more resistant to traditional can-
cer therapeutics. Therefore, new treatment 
strategies are needed particularly true for 
patients with non-favorable risk features.
Despite major advances in understand-
ing the biology of specific subtypes of leu-
kemia, the standard therapy for patients 
with AML has changed little over time. A 
notable exception has been in the treat-
ment of patients with acute promyelocytic 
leukemia (APL) with the introduction of 
all-trans retinoic acid (ATRA) and arsenic 
trioxide (ATO), drugs targeted at the spe-
cific molecular aberration causative of the 
disease [the PML-RARA fusion product of 
t(15;17) translocation, pathognomonic for 
the disease]. Several studies using “chemo-
therapy-free” regimens combining ATRA, 
ATO with or without gemtuzumab ozo-
gamicin (GO) have produced high and 
durable response rate. Although the com-
bination of cytarabine and an anthracy-
cline continues to be the basis for most 
induction and consolidation regimens in 
other types of AML, development of spe-
cific drugs targeting molecular aberrations 
such as mutated FLT3, RAS, and the PI3K 
signaling pathways are showing the way 
for potential personalized therapy in the 
future.
Better understanding of the biology 
of AML has identified new targets for 
therapeutic intervention. One of the best 
examples of this is the identification of 
the mutated form of FLT3 tyrosine kinase 
which confers a worse outcome in the 30% 
of patients whose leukemic cells bear this 
abnormality. Several inhibitors of FLT3 
kinase have been developed and evaluated 
at our institution including lestaurtinib, 
sorafenib, and quizartinib with the latter 
two drugs demonstrating significant activ-
ity. Other potential targets include NPM1 
(reports suggesting a role for ATRA in 
NPM1 mutated diploid AML), c-KIT in 
CBF leukemias, the JAK-STAT signaling 
pathway in post-MPN AML, the MAPK 
pathway in RAS mutated leukemias and 
various cellular signaling components 
which include a number of tyrosine and 
serine/threonine kinases. This ever expand-
ing list of potential targets has advantages 
and disadvantages in terms of therapeutic 
intervention. The advantages include well 
defined hypotheses that can be tested using 
correlative studies to determine whether 
the inhibition of the specific target or 
pathway can be beneficial clinically. The 
potential problem comes from the fact 
that many of these targets are redundant 
and overlapping and as such their specific 
inhibition may not lead to meaningful 
 benefits despite their significant role in leu-
kemic cell survival. It is also clear from early 
studies that the many of these agents are 
able to achieve more meaningful responses 
when combined with traditional agents, 
such as cytarabine and anthracyclines or 
novel agents such as the hypomethylating 
compounds. They are also likely to have a 
major role in the post-remission/consoli-
dation setting where they can and should 
be evaluated for the eradication of minimal 
residual disease (MRD).
Better evaluation of MRD and a better 
understanding of the biology of the leuke-
mogenic cells (“Leukemia stem cells”) may 
allow the development of new agents with 
alternative mode of action active against 
these residual cells. Relapse in AML is the 
result of the resurgence of leukemic cells 
that have escaped induction and con-
solidation therapy and have persisted in 
complete remission (CR). This MRD is 
not detectable by the standard techniques 
used to define CR; therefore, more sensi-
tive techniques such as polymerase chain 
reaction (PCR) and multi-parameter flow 
cytometry (MFC) are used increasingly 
to define MRD. PCR-based strategies to 
detect MRD have been largely limited 
to patients with favorable risk disease 
where the fusion transcripts AML1-ETO, 
CBFB-MYH11, and PML-RARA can be 
monitored. This proportion can be poten-
tially increased using the newly identified 
mutated genes such as FLT3 and NPM1 as 
well as over-expressed genes such as WT1. 
MRD monitoring with flow cytometry 
relies on the idea that AML cells frequently 
have aberrant antigen expression resulting 
from asynchronous antigen-expression, 
cross-lineage antigen expression, antigen 
over-expression, and aberrant light scatter 
properties. Early studies of immunophe-
notypic detection of MRD in AML were 
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based on double antigen staining ana-
lyzed by fluorescence microscopy. More 
recent studies have demonstrated that 
using MFC, monitoring may be appli-
cable to virtually all patients and allow a 
more precise detection of the MRD with 
aberrant phenotype. Such immunophe-
notypic evaluation of MRD by MFC has 
been demonstrated to be useful in pre-
dicting the risk of relapse after achieving 
CR. The identification of leukemia stem 
cells in this setting, using specific markers, 
would be particularly attractive as it may 
allow the application of specific agents 
with the a bility to target and eradicate 
these leukemia-sustaining cells.
We have seen limited progress in the 
treatment of the complex disease, AML, 
over the past several decades. Recent pro-
gress suggests that AML therapy can lead 
the way to unraveling the complexities of 
cancer therapy as a whole and lay further 
foundations to enhance our understand-
ing of carcinogenesis and cancer therapy. 
Similar progress in the understanding of 
the molecular pathogenesis of other hema-
tological neoplasms as well as solid tumors 
is opening the doors toward the develop-
ment of more effective and less toxic target 
specific agents and will no doubt further 
change the strategies of combating and 
curing these disorders. Small molecule 
inhibitors of components of various 
deregulated signaling pathways as well 
as monoclonal antibodies and immune 
based therapies have already dramatically 
altered treatment algorithms in lympho-
mas, leukemias, and myeloma with fur-
ther highly effective agents continuing to 
be developed.
In this journal we are hoping to capture 
the interest of the readers interested in keep-
ing up with these advances through publish-
ing up-to-date, and concise review articles 
summarizing the advances in the field as 
well as original articles which are helping to 
unravel the mysteries of carcinogenesis and 
leading to the new therapeutic advances.
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